A1JS8

Cabozantinib

Created:2025-10-24
Last modified:  2026-02-18

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count61
Chiral Atom Count0
Bond Count65
Aromatic Bond Count23
2D diagram of A1JS8
Toggle HydrogenToggle Labels

Chemical Component Summary

NameCabozantinib
Synonyms~{N}1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-~{N}1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; ONIQOQHATWINJY-UHFFFAOYSA-N
Systematic Name (OpenEye OEToolkits)~{N}1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-~{N}1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
FormulaC28 H24 F N3 O5
Molecular Weight501.506
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC
SMILESOpenEye OEToolkits2.0.7COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F
Canonical SMILESCACTVS3.385 COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC
Canonical SMILESOpenEye OEToolkits2.0.7 COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F
InChIInChI1.06 InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
InChIKeyInChI1.06 ONIQOQHATWINJY-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB08875 
NameCabozantinib
Groups
  • approved
  • investigational
DescriptionCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] Cabometyx has since been granted several additional approvals for endocrine cancers, including differentiated thyroid cancer and neuroendocrine tumors.[L52710]
Synonyms
  • Cabozantinib
  • Cabozantinib malate
Brand Names
  • Cabometyx
  • Cometriq
IndicationCabozantinib, marketed under the brand name Cometriq, is indicated for the treatment of progressive, metastatic medullary thyroid cancer (MTC).[L52715] Cabozantinib, marketed under the brand name Cabometyx, is indicated for the treatment of renal cell carcinoma, alone or as a first-line therapy in combination with [nivolumab].[L52710] It is also indicated for the treatment of hepatocellular carcinoma in patients previously treated with [sorafenib].[L52710] Cabozantanib,marketed under the brand name Cabometyx, is also indicated in adult and pediatric patients ≥12 years of age for the treatment of: - Locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy in patients who are radioactive iodine-refractory or ineligible[L52710] - Previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET)[L52710] - Previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET)[L52710]
Categories
  • Amides
  • Amines
  • Aniline Compounds
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
ATC-CodeL01EX07
CAS number849217-68-1

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Hepatocyte growth factor receptorMKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET...unknowninhibitor
Proto-oncogene tyrosine-protein kinase receptor RetMAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPL...unknowninhibitor
Vascular endothelial growth factor receptor 2MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQ...unknowninhibitor
Vascular endothelial growth factor receptor 1MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLH...unknowninhibitor
Vascular endothelial growth factor receptor 3MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSIS...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682